Shionogi's first-quarter results, released August 3, show revenue of ¥163.3bn for the three months to June 30, up 63.7% from a year earlier, operating profit of ¥66.9bn, up 90.6%, and net profit attributable to shareholders of ¥97.7bn, up 148.2%. All three are records for a first quarter at the company. That net profit figure alone already covers 90.5% of the ¥108bn Shionogi has guided for the whole first half through September.
| Metric | This quarter | Year-ago quarter | Change | Full-year target |
|---|---|---|---|---|
| Revenue | ¥163.3bn | ¥99.8bn | +63.7% | ¥700bn |
| Operating profit | ¥66.9bn | ¥35.1bn | +90.6% | ¥220bn |
| Net profit (parent) | ¥97.7bn | ¥39.4bn | +148.2% | ¥210bn |
The surge has more to do with what Shionogi has bought than what it has sold. On April 1, 2026, the company completed a ¥397.5bn purchase of the edaravone franchise, sold as Radicut in Japan and RADICAVA in the US for the neurodegenerative disease ALS, paying Tanabe Pharma ¥393.0bn in cash plus ¥4.48bn in contingent payments. That outlay, together with dividend payments, helped cut Shionogi's cash and equivalents from ¥711.4bn to ¥298.9bn during the quarter, a fall of ¥412.5bn. Goodwill on the balance sheet more than doubled to ¥64.1bn and intangible assets nearly tripled to ¥562.1bn, though Shionogi says the purchase-price allocation for both the edaravone deal and an earlier increase in its ViiV Healthcare stake is still provisional and subject to revision.
Two other completed deals are also bedding in. Domestic prescription-drug revenue rose 137.3% to ¥33.5bn, with newly consolidated Torii Pharmaceutical, brought to full ownership last year through a tender offer and a squeeze-out, contributing ¥18.8bn and Radicut adding ¥1.8bn. Overseas subsidiary and export revenue rose 196.6% to ¥42.2bn, helped by RADICAVA sales now booked under Shionogi following the April 2026 edaravone business transfer from Tanabe Pharma (US and Canada sales rose 14.6% from what Tanabe Pharma recorded a year earlier) and by continued growth for the antibiotic Fetroja/Fetcroja. Royalty income rose 25.3% to ¥80.1bn, with ¥72.7bn of that tied to royalty payments linked to sales growth in ViiV Healthcare's HIV franchise, a business in which Shionogi separately holds a minority equity stake accounted for under the equity method.
Shionogi left its guidance for the year to March 2027 unchanged: revenue of ¥700bn, operating profit of ¥220bn, net profit of ¥210bn, and an annual dividend of ¥76 per share. Part of the quarter's profit gain came from a deferred tax asset booked at a US subsidiary, recognized because the edaravone business is now expected to produce taxable income there; that cut the tax charge rather than reflecting stronger trading. With the purchase-price accounting for two of the year's biggest deals still unsettled, how much of this quarter's profit holds up depends on figures Shionogi has yet to finalize.